Results 1 to 10 of about 21,414 (116)

Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer

Molecular Therapy - Oncolytics, 2021
Chimeric antigen receptor (CAR) T cells have revolutionized blood cancer immunotherapy; however, their efficacy against solid tumors has been limited. A common mechanism of tumor escape from single target therapies is downregulation or mutational loss of
Richard Boyd
exaly   +3 more sources

Research advances on CD47 in digestive system cancers: from molecular mechanisms to clinical translation [PDF]

Molecular Medicine
CD47 is a major innate immune checkpoint molecule that interacts with signal regulatory protein α (SIRPα) to deliver a “don’t eat me” signal and restrain macrophage-mediated phagocytosis.
Haolin Sun, Chenyu Wei, Jianglan Long, Xiaojia Liu, Quanfu Li, Bangwei Cao   +5 more
doaj   +2 more sources

Deciphering the role of CD47 in cancer immunotherapy

Journal of Advanced Research
Background: Immunotherapy has emerged as a novel strategy for cancer treatment following surgery, radiotherapy, and chemotherapy. Immune checkpoint blockade and Chimeric antigen receptor (CAR)-T cell therapies have been successful in clinical trials ...
Yufeng Shi, Lan Fang, Yu'E Liu
exaly   +3 more sources

CD47 expression is critical for CAR T-cell survival in vivo

Journal for ImmunoTherapy of Cancer, 2023
Background CD47 is an attractive immunotherapeutic target because it is highly expressed on multiple solid tumors. However, CD47 is also expressed on T cells.
Stephen Gottschalk, Phuong Nguyen, Christopher DeRenzo, Giedre Krenciute, Alex N Beckett, Peter Chockley, Shondra M Pruett-Miller, Peter Vogel, Heather Sheppard   +8 more
doaj   +1 more source

Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis

Journal of Immunology Research, 2021
CD47 is a cell surface glycoprotein molecule, belonging to the immunoglobulin superfamily, binding to various proteins including integrins, thrombospondin-1, and signal regulatory protein α (SIRPα).
Huyen Thi La, Dao Bich Thi Tran, Hai Manh Tran, Linh Trong Nguyen   +3 more
doaj   +1 more source

Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo

Frontiers in Oncology, 2022
Targeted therapies hold promise for efficiently and accurately delivering cytotoxic drugs directly to tumor tissue to exert anticancer effects. CD47 is a membrane protein expressed in a variety of malignant tumors and hematopoietic cells, which plays a ...
Zu-Chian Chiang, Zu-Chian Chiang, Zu-Chian Chiang, Shubin Fang, Yang-kun Shen, Dongya Cui, Huanjiao Weng, Dawei Wang, Yuxiang Zhao, Jizhen Lin, Jizhen Lin, Qi Chen   +11 more
doaj   +1 more source

Loss of CD47 alters CD8+ T cell activation in vitro and immunodynamics in mice

OncoImmunology, 2022
CD47 has established roles in the immune system for regulating macrophage phagocytosis and lymphocyte activation, with growing evidence of its cell-intrinsic regulatory roles in natural killer and CD8+ T cells.
Pulak R. Nath, Dipasmita Pal-Nath, Sukhbir Kaur, Arunkumar Gangaplara, Thomas J. Meyer, Margaret C Cam, David D. Roberts   +6 more
doaj   +1 more source

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy

Frontiers in Immunology, 2021
The prosperity of immunological therapy for cancer has aroused enormous passion for exploiting the novel targets of cancer immunotherapy. After the approval of blinatumomab, a bispecific antibody (bsAb) targeting on CD19 for acute lymphoblastic leukemia,
Yan Yang, Zheng Yang, Yun Yang
doaj   +1 more source

The application of HER2 and CD47 CAR-macrophage in ovarian cancer

Journal of Translational Medicine, 2023
Background The chimeric antigen receptor (CAR)-T therapy has a limited therapeutic effect on solid tumors owing to the limited CAR-T cell infiltration into solid tumors and the inactivation of CAR-T cells by the immunosuppressive tumor microenvironment ...
Yizhao Chen, Xiangling Zhu, Hanze Liu, Cunzhi Wang, Yu Chen, Huihui Wang, Yilong Fang, Xuming Wu, Yuting Xu, Chunhua Li, Xinyue Lv, Jinghua Huang, Xintong Han, Ruilin Li, Wenming Hong, Zhiying Yu, Wei Wei, Jiajie Tu   +17 more
doaj   +1 more source

CD47(low) status on CD4 effectors is necessary for the contraction/resolution of the immune response in humans and mice. [PDF]

PLoS ONE, 2012
How do effector CD4 T cells escape cell death during the contraction of the immune response (IR) remain largely unknown. CD47, through interactions with thrombospondin-1 (TSP-1) and SIRP-α, is implicated in cell death and phagocytosis of malignant cells.
Vu Quang Van, Nobuyasu Baba, Manuel Rubio, Keiko Wakahara, Benoit Panzini, Carole Richard, Genevieve Soucy, Denis Franchimont, Genevieve Fortin, Ana Carolina Martinez Torres, Lauriane Cabon, Santos Susin, Marika Sarfati   +12 more
doaj   +1 more source